Alvotech (ALVO) Projected to Announce Quarterly Earnings on Wednesday

Key Points

• Alvotech is expected to report Q3 2026 results after Wednesday’s market close, with analysts forecasting a loss of $0.0197 per share and revenue of $134.22 million. Its earnings call is scheduled for Thursday, November 12, at 8:00 a.m. ET.
• In its previous quarter, Alvotech reported a loss of $0.11 per share, worse than the $0.05 loss analysts expected, while revenue of $106 million exceeded estimates of $103 million.
• Analyst views are mixed: MarketBeat reports an average “Hold” rating and an average price target of $8.25, while shares opened at $4.54 and have traded between $2.94 and $6.53 over the past year.

Alvotech (NASDAQ:ALVO - Get Free Report) will likely be releasing its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Alvotech to announce earnings of ($0.0197) per share and revenue of $134.22 million for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

Alvotech (NASDAQ:ALVO - Get Free Report) last announced its quarterly earnings data on Thursday, August 20th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.06). The firm had revenue of $106.00 million during the quarter, compared to the consensus estimate of $103.00 million. On average, analysts expect Alvotech to post ($0.01) EPS for the current fiscal year and $0.22 EPS for the next fiscal year.

Alvotech Price Performance

NASDAQ:ALVO opened at $4.54 on Wednesday. Alvotech has a 1-year low of $2.94 and a 1-year high of $6.53. The firm has a fifty day simple moving average of $5.30 and a 200 day simple moving average of $4.22.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Bank of America assumed coverage on shares of Alvotech in a research note on Monday, August 24th. They issued a "buy" rating and a $7.00 price target for the company. Wall Street Zen upgraded shares of Alvotech from a "sell" rating to a "hold" rating in a research note on Saturday, October 24th. Weiss Ratings lowered shares of Alvotech from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, October 23rd. UBS Group set a $8.00 target price on shares of Alvotech in a report on Wednesday, September 16th. Finally, Barclays upgraded shares of Alvotech from an "underweight" rating to an "overweight" rating and raised their target price for the company from $4.00 to $8.00 in a research note on Wednesday, September 16th. Four research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $8.25.

About Alvotech

Alvotech is a biotechnology company headquartered in Reykjavík, Iceland, focused on developing and manufacturing biosimilar medicines. Biosimilars are biologic products designed to be highly similar to already approved reference medicines and are intended to expand patient access to complex treatments at potentially lower costs.

The company uses an integrated research, development and manufacturing model and concentrates on therapeutic areas including immunology, ophthalmology, oncology and bone health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.